Filters
The use of hormone therapy poses a small but significant increase in systolic blood pressure (BP) in postmenopausal women with hypertension, a study has found. However, this BP elevation does not lead to increased BP-lowering medication use over time.
A dietary intervention consisting of a plant-based diet, minimal oils, and daily soybeans appears to have favourable effects on vasomotor symptoms and menopause-related quality of life, as reported in a study.
Postpartum cervical length measurements help pinpoint which patients are at heightened risk of subsequent spontaneous preterm birth, as reported in a study.
Children exposed to maternal smoking during pregnancy have higher systolic blood pressure (SBP) and are at a heightened risk of hypertension, a recent study has found.
Breast cancer patients with urogenital atrophy may benefit from intravaginal laser therapy and hyaluronic acid suppositories, with a recent study showing that both help resolve related symptoms equally.
Trabectedin falls short of meeting the prespecified antitumour activity criteria in patients with advanced ovarian (OC) or uterine carcinosarcoma (UC), according to the results of a phase II trial. However, there appears to be a modest clinical benefit in a group of heavily pretreated patients.
A 90-day tenofovir (TFV) regimen combined with a levonorgestrel (LNG) intravaginal ring (IVR), which elutes the drug continuously or cyclically, is safe for use in women and can effectively prevent unintended pregnancies, a recent phase I study has found.
Preoperative administration of gabapentin helps reduce intraoperative pain in women undergoing second-trimester surgical abortion, leading to improved satisfaction with pain management, as shown in a randomized, controlled, double-blind trial.
Achieving pregnancy through in vitro fertilization (IVF) appears to increase the risk of severe maternal morbidity both during singleton or multiple pregnancies, a recent Korea study has found.
New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
